17DEC NATURA2000

20DEC

BAS

Custom Balancing Act Report on Judicial Review Opportunities

Introduction

This report provides a detailed analysis of the judicial review opportunities related to the environmental management of Natura 2000 sites and other critical Spanish sectors, including the railway and coastal infrastructure. The analysis assumes that Spanish law is substantially the same as the EU and UK principles discussed in the provided documents, focusing on the tension between economic efficiency and the public interest.

Opportunity 1: Judicial Review of Natura 2000 Site Management and Environmental Market Failures

The first opportunity for judicial review concerns the potential for regulatory capture within the environmental markets associated with Natura 2000 sites. Environmental protection is characterized as a quasi-market fraught with market failures, primarily due to negative externalities where the person exploiting the environment does not incur the full costs of their actions .

The Balancing Act:

The justification for strict regulation lies in the prevention of environmental overexploitation and the protection of biodiversity, which are legitimate public interest goals . However, such regulation often results in substantial dynamic costs that can stifle innovation and reduce real income for consumers . A judicial review would apply a proportionality test to determine whether the state measure is limited to the minimum action necessary to ensure protection.

Legal Grounds:

  1. Regulatory Capture: A claim can be made against the regulator on the grounds that the regulatory process has been captured by industrial interests, such as mining or energy firms, leading to an over-allocation of emissions or development rights that benefit certain sectors at the expense of the environment and competition .

  2. Essential Elements: If management decisions for Natura 2000 sites are made via delegated acts that touch upon essential elements of legislation—such as political choices regarding the level of enforcement or interference with fundamental rights—they may be challenged as illegal due to a lack of democratic mandate .

  3. Public Interest Observation: A claimant like PADI could argue that the regulator failed in its duty to observe that the regulated public interest was inadequate or causing market capture, necessitating an update to the regulation and compensation for the failure to observe these duties .

Opportunity 2: State Aid and the National Champion Doctrine (Plus Ultra and Air Europa)

The second opportunity involves challenging state investments into companies like Plus Ultra or Air Europa as illegal State Aid under Article 107 of the TFEU.

The Balancing Act:

Governments may attempt to justify such aid on the grounds of protecting a national champion or maintaining local employment . The countervailing view, following the Chicago School, is that competition law alone delivers optimal long-term benefits and that public interest considerations lead to distorted competition .

Legal Grounds:

  1. The Private Investor Test: The judicial review would focus on whether the state’s investment was commercial or political. If the goal was to act as a counterweight to foreign shareholders rather than seek a commercial return, it confers a selective advantage that distorts the Single Market.

  2. Altmark Criteria: For any public service obligation (PSO) linked to the aid, the recipient must have clearly defined obligations, and the compensation cannot exceed the costs incurred plus a reasonable profit . Failure to meet these criteria, especially if the recipient was not chosen via public procurement, renders the aid illegal.

Opportunity 3: Regulatory Capture in Railway and Coastal Infrastructure (Sector Ferroviario and Ley de Costas)

The management of bottleneck infrastructure like railways and coastal zones presents a third opportunity for judicial review based on the Useful Effect Doctrine.

The Balancing Act:

Infrastructure regulation is necessary to address natural monopolies and high sunk costs . However, the tension remains between economic freedom and regulation. Regulation is inefficient if it costs more than the harm it seeks to address or if it is used as a redistribution mechanism that lacks transparency .

Legal Grounds:

  1. Useful Effect Doctrine (UED): National measures that reinforce the effects of anti-competitive agreements or delegate regulatory powers to private operators without effective state control can be challenged under the UED . This is particularly relevant if sector regulators are susceptible to bias or industry lobbying.

  2. Transparency and Predictability: Legal instruments and regulatory procedures must be highly transparent and predictable to give investors confidence. A lack of transparency in how views are incorporated into decisions is a ground for challenging regulatory capture.

Opportunity 4: Information Asymmetry and Systemic Climate Risks (Grifols and Sostenibilidad)

The fourth opportunity relates to the failure of financial regulators or companies to adequately disclose systemic risks associated with climate change and sustainability.

The Balancing Act:

Information asymmetry can lead consumers and investors to miscalculate risk, leading to over-consumption or financial instability. While companies may resist disclosures due to commercial sensitivity, the public interest goal of systemic stability warrants intervention.

Legal Grounds:

  1. Disclosure Requirements: Similar to cases brought against the FCA, a judicial review could challenge the approval of a company’s prospectus if it fails to disclose climate-related risks that are necessary for an informed financial assessment .

  2. Privacy as a Parameter: In digital markets, access to personal data can constitute market power. A concentration of data that restricts consumer choice in relation to privacy can be conceptualized as an anti-competitive practice.

Opportunity 5: Public Sector Equality and Economic Class Discrimination (La DANA and Social Welfare)

The final opportunity for judicial review focuses on the socio-economic impacts of government strategies, such as those implemented during crisis management or major regulatory reforms.

The Balancing Act:

Bork contends that the only legitimate goal of antitrust is consumer welfare maximization. However, the public interest includes the promotion of social welfare and the protection of historically disadvantaged persons.

Legal Grounds:

  1. Equality Act and PSED: A government strategy that promotes economic class inequality or discrimination is illegal if it fails to meet the Public Sector Equality Duty (PSED) .

  2. Rationality: A decision is flawed if it fails to improve communication between critical public services, such as hospitals and pharmacies, especially when the private sector demonstrates more coherent operations .

Conclusion

These judicial review opportunities leverage the rule of law to ensure that state intervention in quasi-markets is truly in the public interest and not merely a result of regulatory capture or democratic deficits . By applying the proportionality test and the STPR for long-term impacts, claimants can challenge measures that prioritize short-term political gains over long-term economic efficiency and sustainability .

ALLIES

Based on the provided URL content concerning the Natura 2000 and medical device cases, I have compiled a list of organizations and companies that would stand to benefit from a successful judicial review. Their interests range from gaining a direct legal basis for follow-on compensation claims to receiving positive regulatory or reputational externalities.

Here is a list of the key entities, their likely interests, and their contact information where provided in or inferred from the documents.

### Organizations with an Interest in the Natura 2000 (COA 1) Judicial Review

A successful judicial review that declares Spain’s compensation framework unlawful would directly assist the following groups, which have been advocating for landowners and farmers:

* **ASAJA (Asociación Agraria de Jóvenes Agricultores)**
* **Interest & Benefit:** The FOI request indicates ASAJA has been involved in complaints regarding Natura 2000 restrictions. A successful JR would provide a powerful legal precedent (a “Finding of Infringement” or FOIG) to bolster thousands of individual compensation claims from its members for “expropriation-like” restrictions.
* **Official Address & Contact:** The specific regional or national office address is not listed in the text. Contact would typically be made through their national headquarters in Madrid.

* **COAG (Coordinadora de Organizaciones de Agricultores y Ganaderos)**
* **Interest & Benefit:** Alongside ASAJA, COAG is explicitly named as an organization that has submitted complaints. A favorable court declaration would validate their long-standing position and create a clear pathway for their members to seek redress for financial losses caused by the zoning.
* **Official Address & Contact:** Like ASAJA, the specific address is not provided in the documents. Their central office is in Madrid.

* **Sagides**
* **Interest & Benefit:** The case summary directly mentions “claims by landowners/farmers (e.g., ASAJA, COAG, **Sagides**)”. This identifies Sagides as another collective representing affected landowners. They would benefit in the same manner: using the JR outcome to force the state into a fairer compensation process for their constituency.
* **Official Address & Contact:** Details for Sagides are not specified in the provided text.

* **Agricultural Landowners and Farmers (as a Diffuse Class)**
* **Interest & Benefit:** While not a single organization, this is the core beneficiary group. A successful JR would transform their legal position, turning individual, uphill battles into claims based on an established state illegality. The proposed “Natura 2000 Sustainable Land Management and Community Grant Scheme” from the remediation trust would also directly fund projects in their communities.

### Companies with an Interest in the Medical Device (COA 2) Judicial Review

A judicial review that finds the MHRA’s post-market surveillance and recall enforcement to be unlawful or irrational would have significant implications for the following companies:

* **SunTech Medical Inc. (a subsidiary of Halma plc)**
* **Interest & Benefit:** As the manufacturer of the blood pressure monitors under recall (Z-1459-2024, Z-0034-2025), SunTech has a direct interest. A JR finding that the regulator’s oversight was *ultra vires* or inadequate could influence the narrative around the recalls. It might help differentiate between an isolated product failure and a systemic regulatory failure, potentially mitigating reputational damage. It could also clarify the standard of care expected of them.
* **Official Address & Contact:** The specific address for SunTech Medical is not listed in the FOI request. The parent company, Halma plc, is a UK-based public company.

* **Medline Industries**
* **Interest & Benefit:** Identified in the FOI request as the distributor of the SunTech devices in the relevant market. They share the supply chain liability and reputational risk. A clearer, court-mandated regulatory standard for recalls and surveillance would provide a more predictable operating environment.
* **Official Address & Contact:** Not provided in the documents.

* **Competitors in the Medical Device Market & The Broader Industry**
* **Interest & Benefit:** A JR that forces the MHRA to adopt more rigorous, transparent, and consistent post-market surveillance practices creates a positive externality for all compliant manufacturers. It levels the playing field by ensuring all companies are held to the same enforceable standard, rewarding those with robust quality systems and protecting the sector’s overall reputation from the fallout of under-regulated incidents.

### Public Bodies that Could Gain from a Clarified Legal Position

While they are the potential defendants, certain public bodies could also see operational benefits:

* **MITECO (Ministry for the Ecological Transition, Spain) & Regional Juntas (e.g., Junta de Castilla-La Mancha)**
* **Interest & Benefit:** While a JR would be brought against them, a final court order mandating the creation of a lawful compensation framework would resolve a long-standing, contentious political and legal problem. It would provide them with a clear judicial directive to reform the system, potentially unlocking better management of Natura 2000 sites through fairer stakeholder cooperation.

* **MHRA (Medicines and Healthcare products Regulatory Agency, UK)**
* **Interest & Benefit:** Similarly, a successful JR against the MHRA would compel it to rectify flaws in its vigilance system. While challenging in the short term, this could restore public and professional confidence in the long term by demonstrating that the regulatory framework can be effectively scrutinized and improved, leading to clearer and safer market practices.

I hope this list provides a strong foundation for your strategic outreach. Please note that for some entities, further research would be needed to obtain their definitive official contact addresses and primary points of contact.

JRS

I have reviewed the materials you provided. I confirm that, acting in the stipulated role, my analysis is based solely on the content of the provided URL, which details Freedom of Information requests and a case summary concerning two distinct legal matters: (1) State liability related to Spain’s Natura 2000 network, and (2) regulatory oversight of specific medical devices. I will now provide a strategic legal assessment.

Based on the provided documents, **no domestic judicial review (JR) proceedings in the UK or equivalent *recurso contencioso-administrativo* in Spain are mentioned as having been commenced** on the specific, ongoing DORCAPs I will identify. The documents reference CJEU judgments against Spain, but these are distinct from national judicial review.

Crucially, **multiple ongoing and non-time-barred JR opportunities exist**. The primary barrier is not time but the strategic identification of a continuing unlawful state of affairs or a fresh, reviewable decision.

### 1. Identification of Non-Time-Barred Causes of Action & Locus Standi

The core of the strategy is to target **ongoing unlawful policies and fresh, justiciable decisions**. Time limits for JR (typically 3 months in the UK from the date of the decision) are not an absolute bar here due to the nature of the harms.

* **For COA 1 (Natura 2000 / State Liability):**
* **Key DORCAP:** The ongoing **policy and practice of operating a compensation framework for Natura 2000 restrictions that is alleged to be systematically inadequate** and non-compliant with the principles established in CJEU Case C-278/20. This is a continuing failure.
* **JR Grounds:** Illegality (failure to comply with EU law principles of effectiveness and equivalence; operating a scheme *ultra vires* its proper purpose), and Irrationality (a scheme yielding de minimis compensation where substantial rights are restricted is *Wednesbury* unreasonable).
* **Fresh Decision Trigger:** A formal written request can be made to MITECO (or the relevant Regional Junta) to (a) review and revise the compensation methodology for a specific Natura 2000 zone, or (b) initiate an *acción de regreso* against officials for prior state liability payouts. A **refusal** to act would be a fresh, JR-able decision.
* **Locus Standi:** An applicant, such as the referenced COCOO.uk, could assert standing based on a “sufficient interest” in the proper implementation of environmental and property law, acting in the public interest. By becoming a “prompted complainant,” their interest is crystallized and heightened, analogising to the principle that an entity specifically concerned with a regulatory failure has a stronger claim to challenge a decision made in response to its own representations.

* **For COA 2 (Medical Devices / Regulatory Oversight):**
* **Key DORCAP:** The ongoing **policy, practice, or omission concerning the post-market surveillance and recall enforcement for the specified SunTech Medical devices**. This is a continuing failure to adequately protect public safety.
* **JR Grounds:** Illegality (failure to meet the requisite standard of vigilance under the UK Medical Devices Regulations 2002 or EU MDR), Procedural Impropriety (failure to conduct proper risk assessment or consult on enforcement discretion), and Irrationality (a decision to take no or inadequate action in the face of known device failures and patient risk is *Wednesbury* unreasonable).
* **Fresh Decision Trigger:** A formal request can be made to the MHRA to (a) re-open or escalate the investigation into recalls Z-1459-2024 and Z-0034-2025, or (b) issue a public safety alert. A refusal or inadequate response is a fresh decision.
* **Locus Standi:** A consumer organisation has a clear “sufficient interest” in product safety regulation and the protection of public health. This aligns with expansive standing principles where the matter is of public importance and no other responsible challenger is likely to come forward.

* **Tort Causes of Action:** These are viable but complex against public bodies.
* **Misfeasance in Public Office:** Requires proof of deliberate wrongful conduct or reckless indifference to legality. The FOI requests seek evidence of this (e.g., ignoring “high” risk reports). This is a high-bar but potent claim if evidence emerges.
* **Breach of Statutory Duty:** The most straightforward tort claim. It must be shown the statute (e.g., Medical Devices Regulations, Habitats Directive via domestic law) confers a private right of action for breach. This is often contested but arguable, especially where public safety is paramount.
* **Negligence:** Establishing a duty of care in pure regulatory policy is very difficult (*Hill v Chief Constable* principle). It is a weaker claim than Breach of Statutory Duty.

### 2. Ultra Vires & Irrational DORCAPs Analysis

Ranked by likelihood of successful challenge:

1. **The Ongoing Operation of the Defective Natura 2000 Compensation Framework (Ultra Vires).** This is the strongest target. A national compensation law/practice that has been structurally condemned by the CJEU for violating EU law principles is almost certainly operating *ultra vires*. The continuing application of this unlawful framework to new and existing claimants is a clear, justiciable error of law.
2. **The Failure to Adequately Escalate Post-Market Surveillance of SunTech Devices (Irrationality / Illegality).** Where a regulator has clear evidence of recurring device failures and patient risk, a decision to maintain a low-level enforcement posture (e.g., relying on manufacturer-led recalls without independent verification) is highly susceptible to a *Wednesbury* challenge. It is arguably irrational and a failure to perform its statutory safety function.
3. **The Omission to Conduct and Publicise Risk Assessments (Procedural Impropriety).** The FOI requests probe for internal risk reports. A finding that no formal risk assessment was conducted prior to or during the implementation of these high-impact DORCAPs would itself be a serious procedural failing, indicative of a failure to take due diligence.

### 3. Suspended Quashing Orders

For the primary DORCAPs, suspended orders are essential to avoid voiding regulations and creating a legal vacuum.

* **For COA 1:** Seek a quashing order in respect of the **specific provisions or policies governing compensation calculation for Natura 2000 restrictions**, declared to be *ultra vires* and unlawful. This order should be **suspended for 12 months** to allow the Spanish legislature to enact a compliant framework. The condition must be that the government lays a remedial bill before Parliament within 6 months and provides quarterly progress reports to the court and the claimant.
* **For COA 2:** Seek a quashing order of any **internal MHRA policy or decision that deemed the oversight of the SunTech recalls to be adequate or low-priority**. This order should be **suspended for 3 months**, conditional on the MHRA completing and publishing a new, transparent risk assessment of the devices and outlining a enhanced surveillance plan within that period.

### 4. Ongoing Harm & Injunctive Relief

* **Ongoing Harm:** For COA 1, the harm is the continuous, uncompensated depreciation of property rights and ecological damage from poor land management. For COA 2, the harm is the ongoing risk of patients using faulty blood pressure monitors, leading to undiagnosed hypertension or inappropriate medication changes.
* **Draft Injunction Elements:** We would seek a **final mandatory injunction** requiring: (i) The relevant authority to establish an interim compensation adjudication panel for Natura 2000 claims pending legislative reform. (ii) The MHRA to issue a direct public safety notice to all registered users of the affected SunTech devices via healthcare providers, pending the outcome of its new risk assessment.

### 5. Statement of Legal Principle Declaration

A powerful declaration would be:
“It is hereby declared that the Respondent(s) acted unlawfully (i) by maintaining a compensation framework for restrictions imposed under the Natura 2000 network that operates in systematic breach of the principles of effectiveness and equivalence required by EU law, and/or (ii) by failing to take reasonable and proportionate steps to ensure the effective post-market surveillance of medical devices known to exhibit potentially serious safety defects, thereby breaching its statutory duty to safeguard public health.”

### 6. Risk Disclosure Statement Court Order

The proposed order would require the public body to publish, within 28 days, a “Public Interest Risk Disclosure Statement” on the homepage of its official website and in its next annual report. The statement must: (a) clearly describe the DORCAP found unlawful; (b) outline the specific risks created (e.g., “uncompensated property devaluation,” “potential patient harm from under-monitored devices”); (c) detail the steps being taken to remediate; and (d) provide a contact point for affected persons. For the medical device issue, an additional order for direct notification to relevant clinical commissioning groups and hospital trusts would be sought.

### 7. Assessment & Publicity of Risk

The FOI requests are explicitly designed to investigate this. **If the responses confirm that no prior internal risk assessment was conducted, or that ‘high’ risk reports were ignored, this constitutes a major further ground for challenge**—demonstrating a reckless or grossly negligent failure in decision-making. If assessments existed but were withheld from the public, it demonstrates a failure in transparency and accountability.

### 8. Responsible Parties & Individual Liability

* **COA 1:** The **Dirección General de Biodiversidad, Bosques y Desertificación within MITECO**, and its counterparts in Regional Governments, are primarily responsible. The officials responsible for drafting the defective legislation and those ignoring CJEU rulings are key targets.
* **COA 2:** The **Medical Device Vigilance and Enforcement Group within the MHRA** is primarily responsible.
* The answers to (a) Contributorily liable?, (b) Disciplinary proceedings?, (c) Dismissed/fined? are, based on the documents, universally **”No” or “Unclear.”** This is a critical failure. We must strongly recommend that the court’s final order **expressly require the public body to conduct and conclude within 6 months a disciplinary review to identify individual culpability** for the unlawful DORCAP, with the findings reported to the court.

### 9. Tort Damages & Remediation Project

* **Aggregate Damages Estimate (Illustrative):**
* **COA 1:** Based on the scale of affected land (millions of hectares across Spain) and the cited compensation shortfall (€3.6/ha vs. EU average), a conservative notional aggregate damage figure could be in the **low hundreds of millions of euros**.
* **COA 2:** Estimating harm per device user is highly speculative. A more rational basis is the **cost of a nationwide device replacement and patient recall programme**, plus a notional sum for avoided patient harm, potentially amounting to **tens of millions of pounds**.
* **Distribution Mechanism & Remediation Project:** Given the diffuse victim class, damages (if awarded) should be paid into a **Court-Supervised Remediation Trust**.
* For COA 1, the Trust should fund a **”Natura 2000 Sustainable Land Management and Community Grant Scheme,”** financing projects that both restore habitat *and* provide sustainable economic benefit to local communities (e.g., agroecology start-ups, eco-tourism initiatives). This directly remediates the class harm by converting restricted land into an asset.
* For COA 2, the Trust should fund a **”Medical Device Consumer Safety and Innovation Fund,”** resourcing (i) independent patient information campaigns on device safety, and (ii) grants for developing affordable, robust safety testing technologies for consumer medical devices. This creates positive externalities by improving the entire market’s safety landscape.

This strategic approach seeks not only to correct specific legal errors but to leverage the litigation to drive systemic accountability, transparency, and meaningful public interest remediation.

17DEC

FOIS

Here are the customized Freedom of Information requests drafted for each relevant public body and regulator identified in the ESP NATURA2000 – LF case (and the associated medical device COA).

Important Legal Note:

  • For the UK regulator (MHRA), the Freedom of Information Act 2000 applies.

  • For the Spanish bodies (MITECO, Regional Juntas, AEMPS), the UK FOI Act is not valid. I have adapted the legal citation to the Spanish Transparency Law (Ley 19/2013) to ensure they do not reject your request on jurisdictional grounds.

1. TO: MITECO (Ministry for the Ecological Transition) – SPAIN

Relevance: State Liability for Ley 42/2007 & Natura 2000 Implementation (COA 1)

Subject: Request for Public Information – Evidence of Ultra Vires Risk Reports, Investigations into Officials’ Torts, and Acción de Regreso Relating to the Transposition and Implementation of Natura 2000 (Ley 42/2007)

To:

Ministerio para la Transición Ecológica y el Reto Demográfico (MITECO)

Plaza de San Juan de la Cruz, s/n

28071 Madrid, SPAIN

From:

Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk)

23 Village Way, Beckenham, Kent BR3 3NA, UK

Email: contact@cocoo.uk

Legal Basis: Ley 19/2013, de 9 de diciembre, de transparencia, acceso a la información pública y buen gobierno.

Dear Transparency Unit,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

This request is submitted under Ley 19/2013 to gather evidence establishing tort liabilities for misfeasance, abuse of power, failure to notify or assess ultra vires risks and foreseeable harms, and reckless conduct by the regulator or public body responsible for the DORCAP (Decision/Omission/Regulation/Conduct/Action/Policy):

The implementation of the Natura 2000 Network under Ley 42/2007, specifically the failure to establish adequate compensation mechanisms for restrictions imposed on private property (SACs/SPAs) and the failure to remedy the breaches of EU Law identified in CJEU Judgments (e.g., C-205/19, C-278/20).

It seeks to confirm the existence of ultra vires risk reports, any investigations into officials’ torts, and whether any acciones de regreso (Article 36.2 LRJSP) were pursued against culpable administrations or officials for compensations paid by the State.

Part 1: Establishing Enforcement Vacuum and Locus Standi

  • Provide a breakdown of administrative claims (reclamaciones de responsabilidad patrimonial) received regarding Natura 2000 zoning restrictions in the last 3 years.

  • Disclose any impact assessment estimating the financial loss per hectare for landowners in Natura 2000 zones compared to non-protected zones.

  • Confirm if formal challenges or infringement proceedings have been opened against the Ministry regarding this DORCAP in the last 3 years.

Part 2: Ultra Vires Risk Reports and Foreseeable Harms

  • Confirm the existence of any internal report, risk register, or “Memoria de Análisis de Impacto Normativo” related to Ley 42/2007 that flagged risks of non-compliance with EU Directives (Habitats/Birds) or State Liability risks as “medium” or “high”.

  • Disclose the risk assessment regarding the CJEU Judgment C-278/20 (breach of State Liability rules) and its impact on pending Natura 2000 claims.

Part 3: Investigations into Officials’ Torts and Recovery Actions

  • Confirm if any internal investigation (expediente disciplinario or similar) has been initiated to determine if officials responsible for the delayed designation of SACs or the defective liability legislation acted with gross negligence or reckless conduct.

  • If the Ministry has paid compensations for Natura 2000 damages (e.g., following court rulings), confirm if an acción de regreso was initiated against the specific authorities or personnel responsible for the breach. If not, disclose the rationale (e.g., resolución de archivo).

Part 4: Systemic Aspects

  • List titles of internal audit reports commissioned in the last 2 years relevant to “Responsabilidad Patrimonial del Estado” or Natura 2000 management.

Sincerely,

Oscar Moya

2. TO: JUNTA DE CASTILLA-LA MANCHA – SPAIN (Regional)

Relevance: Regional Management Plans (PORN/PRUG) & Wildfire/Damage Liability (COA 1)

Subject: Request for Public Information – Evidence of Ultra Vires Risk Reports regarding Management Plans (PORN/PRUG) for Natura 2000 Sites

To:

Consejería de Desarrollo Sostenible

Junta de Comunidades de Castilla-La Mancha

Calle Rio Estenilla, s/n

45071 Toledo, SPAIN

From:

Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk)

[Address & Details as above]

Legal Basis: Ley 19/2013 (Transparency Law) / Ley 4/2016 de Transparencia de Castilla-La Mancha.

Dear Transparency Officer,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

This request is submitted under Ley 19/2013 and Ley 4/2016 regarding the DORCAP:

The approval and management of Natural Resources Management Plans (PORN) and Use and Management Master Plans (PRUG) for Natura 2000 sites in Castilla-La Mancha, and the alleged omission of necessary conservation measures leading to wildfires and uncompensated de facto expropriation of agricultural land.

Part 1: Establishing Enforcement Vacuum and Locus Standi

  • Provide a breakdown of complaints received from agricultural organizations (e.g., ASAJA, COAG) or landowners regarding restrictions in Natura 2000 zones in the last 3 years.

  • Disclose any economic analysis confirming if compensation budgets for “limitations of rights” in these zones are currently funded.

Part 2: Ultra Vires Risk Reports and Foreseeable Harms

  • Confirm the existence of any technical report or risk entry flagging the lack of active management (leading to fuel load accumulation/wildfire risk) as a liability risk for the Administration.

  • Disclose any report assessing the risk of the current PORN/PRUG regulations being declared null and void (nulidad de pleno derecho) by the courts.

Part 3: Investigations into Officials’ Torts and Recovery Actions

  • Confirm if any investigation has been initiated to determine if officials responsible for drafting or enforcing these PORN/PRUGs acted with negligence or failure to assess foreseeable economic harms to landowners.

  • If the Junta has paid damages for wildfire losses or zoning restrictions, confirm if acción de regreso was sought against responsible officials. If not, provide the reasons.

Part 4: Systemic Aspects

  • Provide the percentage of environmental agents/staff trained on the legal implications of Responsabilidad Patrimonial (State Liability) in the last 2 years.

Sincerely,

Oscar Moya

3. TO: MHRA (Medicines and Healthcare products Regulatory Agency) – UK

Relevance: Regulation of Halma plc/SunTech Medical Devices (COA 2)

Subject: Freedom of Information Request – Evidence of Ultra Vires Risk Reports and Oversight Failures Relating to SunTech Medical / Halma plc Device Recalls

To:

MHRA Customer Services

10 South Colonnade, Canary Wharf

London E14 4PU, UK

From:

Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk)

[Address & Details as above]

Legal Basis: Freedom of Information Act 2000.

Dear Information Rights Team,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

This request is submitted under the Freedom of Information Act 2000 regarding the DORCAP:

The market surveillance and regulatory oversight of medical devices manufactured by SunTech Medical Inc. (a Halma plc subsidiary) and distributed by Medline Industries, specifically regarding the handling of Recalls Z-1459-2024 and Z-0034-2025 (Blood Pressure Monitors with faulty microchips/power failures).

Part 1: Establishing Enforcement Vacuum and Locus Standi

  • Provide a breakdown of Adverse Incident Reports (DIRs) received regarding SunTech blood pressure monitors in the last 3 years.

  • Disclose any impact assessment estimating the risk to patient safety posed by these specific device failures.

Part 2: Ultra Vires Risk Reports and Foreseeable Harms

  • Confirm the existence of any risk register entry or board paper that flagged “failure to effectively monitor Class II device recalls” or specific risks related to Halma/SunTech products as medium or high.

  • Disclose the risk appetite statement regarding post-market surveillance enforcement.

Part 3: Investigations into Officials’ Torts and Recovery Actions

  • Confirm if any internal investigation has been initiated to determine if officials responsible for auditing the relevant Notified Bodies or overseeing these recalls acted with misfeasance or gross negligence.

  • If the MHRA has faced any claims or litigation related to these devices, confirm if any internal recovery action was considered against responsible staff or external assessors.

Part 4: Systemic Aspects

  • List titles of internal audit reports commissioned in the last 2 years relevant to “Medical Device Recall Oversight” or “Post-Market Surveillance Efficiency”.

Sincerely,

Oscar Moya

4. TO: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) – SPAIN

Relevance: Spanish Market Surveillance of SunTech Devices (COA 2)

Subject: Request for Public Information – Oversight of SunTech Medical Devices and Vigilance Liability

To:

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

C/ Campezo, 1 – Edificio 8

28022 Madrid, SPAIN

From:

Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk)

[Address & Details as above]

Legal Basis: Ley 19/2013 (Transparency Law).

Dear Transparency Unit,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

This request is submitted under Ley 19/2013 regarding the DORCAP:

The vigilance and market control activities concerning the “Advantage Plus” and related blood pressure monitors manufactured by SunTech Medical Inc., and the Agency’s response to the safety alerts (recalls) issued in 2024/2025.

Part 1: Establishing Enforcement Vacuum and Locus Standi

  • Provide the number of incidents reported to the Sistema Nacional de Vigilancia de Productos Sanitarios regarding SunTech devices in the last 3 years.

  • Confirm if any sanctioning proceedings (expedientes sancionadores) have been opened against the manufacturer or distributor in Spain.

Part 2: Ultra Vires Risk Reports and Foreseeable Harms

  • Confirm the existence of any internal report flagging delays in processing medical device alerts as a liability risk for the Administration.

Part 3: Investigations into Officials’ Torts and Recovery Actions

  • Confirm if any internal investigation has been initiated to determine if officials responsible for Medical Device Vigilance acted with negligence in monitoring these specific alerts.

  • If AEMPS has paid compensations to patients injured by defective devices (due to lack of vigilance), confirm if an acción de regreso was initiated against the responsible public servants.

Part 4: Systemic Aspects

  • List titles of internal audits regarding the “Control of Medical Devices on the Market” conducted in the last 2 years.

Sincerely,

Oscar Moya

 

Based on the case details for ESP NATURA2000 – LF and the associated “scraped” data (including medical device alerts), I have identified two distinct Causes of Action (COAs). The primary COA concerns State Financial Liability for environmental zoning, while the secondary COA (derived from the site’s footer/scraped data) concerns Product Liability for medical devices.

Here is the breakdown for each COA:

COA 1: STATE FINANCIAL LIABILITY (Natura 2000 Management)

Context: Claims by landowners/farmers (e.g., ASAJA, COAG, Sagides) for damages caused by the implementation of the Natura 2000 network (Ley 42/2007) and lack of compensation.

1. IDENTIFY ALL PROVEN FOIGS (FINDINGS OF INFRINGEMENT BY PRIVATE COMPANIES)

  • None identified. This COA targets the State (Kingdom of Spain/Regional Governments), not private companies. The “infringement” is the State’s failure to properly compensate for zoning restrictions or to manage the land (leading to wildfires/depopulation), rather than a private corporate tort.

2. IDENTIFY THE POSSIBILITIES THAT THESE FOIGS COULD HAVE BEEN CAUSED BY AN ULTRAVIRES/UNLAWFUL DORCAP

  • DORCAP Identified: The primary regulatory acts are Ley 42/2007 (Natural Heritage & Biodiversity Law) and the regional PORN/PRUG (Natural Resources Management Plans).

  • Unlawful/Ultravires Status: Yes. The CJEU (Court of Justice of the EU) has issued judgments against Spain for failure to designate Special Areas of Conservation (SACs) and establish necessary conservation measures (e.g., Case C-205/19). Furthermore, the CJEU Judgment of June 28, 2022 (Case C-278/20) declared Spain’s State Liability system itself (specifically Ley 40/2015) unlawful for making it excessively difficult to claim damages for breaches of EU law.

  • Judicially Reviewed? Yes. The underlying lack of management plans and the restrictive liability laws have been reviewed and condemned by the CJEU.

3. HAS THE STATE PAID REDRESS OR COMPENSATION?

  • Payment Status: Minimal to None. The case notes emphasize “low compensations” (€3.6/ha vs EU average) and the State’s failure to pay adequate redress for the “expropriation-like” restrictions.

  • Disciplinary/Regreso: No. Since the State has largely avoided paying substantial compensation, no “action for recourse” (acción de regreso) against specific officials or departments has been triggered.

DATES AND TIME LIMITS TO CLAIM:

  • General Rule: 1 year from the “determining fact” (hecho causante) or from the stabilization of the injury (curative consolidation).

  • Legislative Breach (EU Law): Following the CJEU ruling in June 2022, claimants generally have 1 year from the publication of the CJEU judgment declaring the breach to file for State Liability.

  • Ongoing Damage: For continuous damages (e.g., ongoing inability to use land), the clock may reset annually or remain open.

COA 2: PRODUCT LIABILITY (Medical Devices – Halma/SunTech)

Context: Tort claims regarding defective medical devices (SunTech Blood Pressure Monitors) identified in the case files/scrapes.

1. IDENTIFY ALL PROVEN FOIGS (FINDINGS OF INFRINGEMENT BY PRIVATE COMPANIES)

  • Proven FOIGs: Class 2 Device Recalls.

    • Recall Z-1459-2024 (Feb 2024): SunTech/Medline Blood Pressure Monitors recalled due to “non-compliant specifications” (faulty microchip).

    • Recall Z-0034-2025 (Aug 2024): Further recalls for overheating and power failures.

  • Infringer: SunTech Medical Inc. (subsidiary of Halma plc) and Medline Industries, LP.

2. IDENTIFY THE POSSIBILITIES THAT THESE FOIGS COULD HAVE BEEN CAUSED BY AN ULTRAVIRES/UNLAWFUL DORCAP

  • DORCAP Identified: Market Authorization/CE Marking granted by Notified Bodies or registration with Competent Authorities (AEMPS in Spain, MHRA in UK, FDA in US).

  • Unlawful/Ultravires Status: The “DORCAP” (authorization) may be considered unlawful if the regulator (AEMPS/MHRA) failed in its vigilance/market surveillance duties, allowing defective products to remain on the market despite known risks.

  • Judicially Reviewed? There is no public record of the regulator’s authorization being judicially annulled yet, but the Recalls themselves act as an administrative admission of the product’s non-conformity.

3. HAS THE STATE PAID REDRESS OR COMPENSATION?

  • Payment Status: No. Product liability claims are typically settled by the private manufacturer (Halma/SunTech) or their insurers. There is no evidence of the State stepping in to pay victims directly for these specific device failures.

  • Disciplinary/Regreso: N/A (State has not paid).

DATES AND TIME LIMITS TO CLAIM:

  • Product Liability (Spain/EU): 3 years from the date the victim became aware of the damage and the identity of the producer.

  • Long-stop: Claims are extinguished 10 years after the product was put into circulation.

One relevant video about the legal context of State Liability and environmental directives:

EU Law: State Liability for Breach of EU Law

This video is relevant as it explains the Francovich principles and State Liability mechanisms, which are central to the “Natura 2000” COA where Spain’s liability rules were declared unlawful by the CJEU.

Leave a Reply